Prima: we're OK until 2004
07 August, 2003 by Melissa TrudingerDespite dwindling cash reserves, Prima BioMed has reassured the Australian Stock Exchange that it has enough resources to support it at least through the first quarter of 2004.
Biostart invests in Qld start-up Farmacule
06 August, 2003 by Graeme O'NeillQueensland's government has bought a slice of farming's value-added future with a $125,000 investment in Farmacule Bioindustries..
Prana surges on new Alzheimer's lead
05 August, 2003 by Graeme O'NeillShares in Melbourne-based Prana Biotechnology Ltd (ASX:PBT, NASDAQ:PRAN) surged 18 per cent today on news that the company had selected a new, more potent lead compound as a potential preventative therapy and treatment for Alzheimer's disease and related neurodegenerative disorders.
Cochlear inventor: study confirmed my research
01 August, 2003 by Melissa TrudingerCochlear implant inventor Prof Graeme Clark said today that a US study released this week on the risk of meningitis in children receiving cochlear implants confirmed his findings from many years of research.
Clinical Cell Culture expands market
01 August, 2003 by Jeremy TorrWA based Clinical Cell Culture (C3) has signed a deal with US company Ventrex to manufacture the company’s ReCell autologous skin harvesting device, primarily for the plastic and cosmetic surgery markets.
Starpharma to launch clinical trials for HIV gel
01 August, 2003 by Melissa TrudingerStarpharma has been given the all-clear from the US FDA to begin clinical trials on their dendrimer-based microcidal gel for prevention of HIV infection.
BresaGen Q4 results show dwindling cash reserves
31 July, 2003 by Melissa TrudingerAdelaide-based company BresaGen only has enough cash to last until December, according to figures released by the company today.
Axon workstation wins R&D award
31 July, 2003 by Iain ScottASX-listed Axon Instruments has picked up an R&D 100 award for its OpusExpress 6000A electrophysiology workstation.
Australia to play role in bovine genome project
30 July, 2003 by Pete YoungA $100 million international project to sequence the bovine genome is being launched following an intensive lobbying effort in which CSIRO played a key role.
Kiwis cut lab rat rates
29 July, 2003 by Jeremy TorrA new report by New Zealand's National Animal Ethics Advisory Committee (NAEAC) indicates that NZ researchers are now less inclined to reach for the rodent than in previous years, with a 17 per cent drop in the number of animals being used for research, testing or teaching last year.
Biotron files SARS therapeutic patent
29 July, 2003 by Jeremy TorrResearchers at Biotron have filed a patent covering the blocking of specific ion channel activity formed within the E protein of the SARS virus, offering a potentially new treatment for the disease.
Medica raises $4.3m for biotech investees
29 July, 2003 by Pete YoungPooled development fund Medica Holdings has completed a fund-raising trifecta for its stable of biotech investee companies.
BIF grants supports acne therapeutic
28 July, 2003 by Jeremy TorrSydney-based DermaTech Laboratories has scored a AUD$360,000 Biotechnology Innovation Fund grant from the Commonwealth government to research the development of a bacteria-neutral acne lotion.
Polymerat cheered by new development agreements
28 July, 2003 by Pete YoungMaterials science start-up Polymerat has glimpsed light at the end of the tunnel by signing its first joint product development agreements with established biotechs.
Bayer GM canola gets green light for commercial release
25 July, 2003 by Iain ScottThe Office of the Gene Technology Regulator has given Bayer CropScience the green light to commercially release its InVigor genetically modified canola.
